Patients with T2D should be treated with the double target of achieving HbA1c goals and the use of glucose lowering drug with proven CV and renal benefit, particularly GLP-1 receptor agonists and SGLT-2 inhibitors, with or without metformin [17, 37, 40] -in fact, a recent study performed in Mexico has shown that the inadequate control of diabetes is associated with an increased risk of premature death and CV complications [41]-, unfortunately, as our study showed, this percentage was markedly low in Mexico, even worse than in the general population of the CAPTURE study. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.